Thalidomide-induced severe hepatotoxicity

Pharmacotherapy

Volumn 26, Issue 7 I, 2006, Pages 1018-1022

  Hanje, A James ^a,b   Shamp, Jennifer L ^a   Thomas, Fred B ^a   Meis, Greg M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Department of Internal Medicine   (United States)

Author keywords

Hepatotoxicity; Multiple myeloma; NASH; Nonalcoholic steatohepatitis; Thalidomide

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEXAMETHASONE; THALIDOMIDE;

ABDOMINAL DISCOMFORT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DECREASED APPETITE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; MULTIPLE MYELOMA; NAUSEA; NONALCOHOLIC FATTY LIVER; RARE DISEASE; RISK ASSESSMENT;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY; DEXAMETHASONE; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATITIS, TOXIC; HUMANS; LIVER FUNCTION TESTS; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 33745712748     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.7.1018     Document Type: Article

References (34)

1. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4.
2. Blade J, Esteve J, Rosinol L, et al. Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol 2001;28:588-92.
3. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide with dexamethasone for resistant multiple myeloma. Br J Haematol 2003;121:768-71.
4. Dimopoulos M, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001;12:991-5.
5. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
6. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100:1168-71.
7. Franks M, Macpherson G, Figg W. Thalidomide. Lancet 2004;363:1802-11.
8. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-99.
9. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals in the liver, 2nd ed. Philadelphia: Lippincott, 1999:433.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
11. Mofrad P, Contos M, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
12. Bacon B, Farahvash M, Janney C, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-9.
13. Marcos A, Fischer R, Ham J, et al. Selection and outcome of living donors for adult-to-adult right lobe transplantation. Transplantation 2000;69:2410-15.
14. Clark T, Edom N, Larson J, Lindsey LJ. Thalidomide: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf 2001;24:87-117.
15. Trojan A, Chasse E, Gay B, Pichert G, Taverna C. Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma. Ann Oncol 2003;14:501-2.
16. Fowler R, Imrie K. Thalidomide-associated hepatitis: a case report. Am J Hematol 2001;66:300-2.
17. McCormick P, Scott F, Epstein O, Burroughs AK, Scheuer PJ, McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind, placebo-controlled pilot study. J Hepatol 1994;21:496-9.
18. Celgene Corporation. Thalomid capsules (thalidomide) product labeling. Warren, NJ; 1998.
19. Celgene Corporation. New drug application (NDA) 20-785. Thalidomide for the treatment of erythema nodosum leprosum. Warren, NJ; 1996.
20. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997;336:1487-93.
21. Sampario E, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunological manifestations of erythema nodosum leprosum. J Infect Dis 1993;168:408-14.
22. Shannon E, Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-α by mononuclear cells. Immunopharmacol Immunotoxicol 1996;18:59-72.
23. Sampario EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J Exp Med 1991;173:699-703.
24. Makonkawkeyoon S, Limson-Pobre RNR, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:5974-8.
25. Sampario EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon γ induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992;175;1729-37.
26. Tilg H, Diehl A. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
27. Kugelmas M, Hill D, Vivian B, et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-19.
28. Wigg A, Roberts-Thomson I, Dymock R, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-11.
29. Feingold KR, Soued M, Grunfeld C. Tumor necrosis factor stimulates DNA synthesis in the liver of intact rats. Biochem Biophy Res Commun 1988;153:576-82.
30. Knight B, Yeoh GC, Husk KL, et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000;192:1809-18.
31. Akerman P, Cote P, Yang SQ, et al. Antibodies to tumor necrosis factor-α inhibit liver regeneration after partial hepatectomy. Am J Physiol 1992;263:G579-85.
32. Akhurst B, Matthews V, Husk K, Smyth MJ, Abraham LJ, Yeoh GC. Differential lymphotoxin-β and interferon γ signaling during mouse liver regeneration induced by chronic and acute injury. Hepatology 2005;41:327-35.
33. Serandour AL, Loyer P, Gamier D, et al. TNF-α-mediated extracellular matrix remodeling is required for multiple division cycles in rat hepatocytes. Hepatology 2005;41:478-86.
34. Brooling JT, Campbell JS, Mitchell C, Yeoh GC, Fausto N. Differential regulation of rodent hepatocyte and oval cell proliferation by interferon γ. Hepatology 2005;41:906-15.